PUBLISHER: Grand View Research | PRODUCT CODE: 1985847
PUBLISHER: Grand View Research | PRODUCT CODE: 1985847
The U.S. healthcare passive cold chain packaging market size was valued at USD 2.22 billion in 2025 and is projected to reach USD 5.45 billion by 2033, expanding at a CAGR of 11.9% from 2026 to 2033. The industry is primarily driven by the rising production and distribution of temperature-sensitive biologics, vaccines, and advanced therapies, which demand reliable, validated passive temperature control solutions.
Additionally, cost-efficiency and operational simplicity of passive systems make them widely adopted across domestic healthcare logistics, especially for last-mile and direct-to-patient shipments.
The rising demand for temperature-sensitive biologics and vaccines is one of the most significant growth drivers for the U.S. healthcare passive cold chain packaging industry. Unlike conventional pharmaceuticals, biologics such as monoclonal antibodies, cell and gene therapies, and recombinant proteins are highly vulnerable to temperature variations. Even limited exposure outside recommended ranges can compromise product efficacy, making reliable passive cold chain solutions essential for protecting drug quality during storage and distribution.
The U.S. remains a global leader in biologics development and commercialization, supported by strong pharmaceutical innovation and increasing approvals of advanced therapies. These products require distribution across hospitals, specialty pharmacies, clinical trial sites, and increasingly direct-to-patient channels. Passive cold chain packaging, including insulated shippers, phase change materials, and gel packs, offers a scalable and cost-effective approach to ensure temperature control without the operational burden of fully active refrigeration systems.
Vaccines further strengthen this demand, particularly with the expansion of immunization programs, seasonal influenza supply chains, and broader preparedness for public health emergencies. Vaccine distribution involves high shipment volumes, variable transit durations, and complex last-mile delivery requirements. Passive packaging is widely preferred due to its flexibility, lower cost structure, and validated performance across diverse climate and transportation conditions.
Moreover, the increasing adoption of e-commerce in healthcare logistics is becoming a major growth driver for the industry. Healthcare distribution is expanding beyond traditional hospital and wholesaler channels toward digital ordering platforms, specialty pharmacy networks, and direct-to-patient delivery models. For example, specialty pharmacies shipping biologics for rheumatoid arthritis or multiple sclerosis now rely heavily on insulated parcel shippers to ensure products remain within the required 2-8°C range during doorstep delivery. This structural shift is significantly increasing demand for validated passive cold chain packaging solutions.
U.S. Healthcare Passive Cold Chain Packaging Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. healthcare passive cold chain packaging market report based on product, temperature requirement, end use, and region: